Close

Roth Capital Affirms Bioblast Pharma (ORPN) at 'Buy'; Extension Study Data Shows Sustainable Improvements

September 12, 2016 12:43 PM EDT Send to a Friend
Roth Capital affirms Bioblast Pharma Ltd. (Nasdaq: ORPN) at Buy with a price target of $15 after the company announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login